GSK-3358699 (GlaxoSmithKline)

N/A

Report date: 2023/01/01 12:03:51
NME

Base Information

Drug NameGSK-3358699 (GlaxoSmithKline)
Drug Alias NameGSK-3358699
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionImmunomodulatorsBromodomain and extra terminal domain protein inhibitors
TargetsBromodomain and extra terminal domain protein
Therapy Area/IndicationsArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesGlaxosmithkline Plc
Inactive CompaniesN/A
Active IndicationsArthritis, Rheumatoid
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A